No Data
No Data
Maintaining Hold on AlloVir Amid Financial Performance and Strategic Uncertainty
Morgan Stanley Maintains AlloVir(ALVR.US) With Sell Rating, Maintains Target Price $0.5
Morgan Stanley Sticks to Its Sell Rating for AlloVir (ALVR)
AlloVir | 10-Q: Q2 2024 Earnings Report
Here's Why AlloVir (NASDAQ:ALVR) Must Use Its Cash Wisely
Cytomegalovirus Infection Therapeutics Research 2024: Comprehensive Insights About 15+ Companies and 20+ Pipeline Drugs Featuring Vir, SpyBiotech, Moderna, VBI, Trellis Bioscience, GSK, & AlloVir
No Data